Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.

Here are the top 10 best-selling, brand-name drugs of 2024. Bristol Myers Squibb (BMY) and Ono Pharmaceutical’s Opdivo, a treatment for melanoma and other cancers, generated $9.3 billion in ...

A dispute over a microscopic enzyme is threatening Merck & Co. plans to sell a new version of Keytruda, the cancer drug that generates nearly half of the company’s sales. Merck has been tweaking ...

developed it and brought it to market in a host of cancer indications under the brand name Keytruda. Neurotech's cell therapy gets FDA nod for eye disorder MacTe... Neurotech Pharma's cell therapy ...

Pembrolizumab is currently approved under the brand name Keytruda as a monotherapy and in combination regimens for patients with metastatic or with unresectable, recurrent HNSCC.

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in 2028, Jared Hopkins of The Wall Street Journal reports.

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.